Avadel Pharmaceuticals PLC (NASDAQ:AVDL) — Market Cap & Net Worth
Market Cap & Net Worth: Avadel Pharmaceuticals PLC (AVDL)
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) has a market capitalization of $2.12 Billion ($2.12 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5883 globally and #1903 in its home market, demonstrating a 0.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avadel Pharmaceuticals PLC's stock price $21.64 by its total outstanding shares 98151471 (98.15 Million). See Avadel Pharmaceuticals PLC capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Avadel Pharmaceuticals PLC Market Cap History: 2015 to 2026
Avadel Pharmaceuticals PLC's market capitalization history from 2015 to 2026. Data shows growth from $1.20 Billion to $2.12 Billion (1.16% CAGR).
Index Memberships
Avadel Pharmaceuticals PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.09% | #153 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #671 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.12% | #96 of 263 |
Weight: Avadel Pharmaceuticals PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Avadel Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avadel Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.10x
Avadel Pharmaceuticals PLC's market cap is 6.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.20 Billion | $173.21 Million | $40.66 Million | 6.92x | 29.48x |
| 2016 | $1.02 Billion | $150.25 Million | -$41.28 Million | 6.79x | N/A |
| 2017 | $804.84 Million | $172.74 Million | $67.25 Million | 4.66x | 11.97x |
| 2018 | $253.23 Million | $103.27 Million | -$95.30 Million | 2.45x | N/A |
| 2019 | $741.04 Million | $59.22 Million | -$33.23 Million | 12.51x | N/A |
| 2020 | $655.65 Million | $22.33 Million | $7.03 Million | 29.36x | 93.29x |
| 2022 | $702.76 Million | $1.50 Million | -$137.46 Million | 469.76x | N/A |
| 2023 | $1.39 Billion | $27.96 Million | -$160.28 Million | 49.56x | N/A |
| 2024 | $1.03 Billion | $169.12 Million | -$48.83 Million | 6.10x | N/A |
Competitor Companies of AVDL by Market Capitalization
Companies near Avadel Pharmaceuticals PLC in the global market cap rankings as of August 1, 2026.
Key companies related to Avadel Pharmaceuticals PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Avadel Pharmaceuticals PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Avadel Pharmaceuticals PLC's market cap moved from $1.20 Billion to $ 2.12 Billion, with a yearly change of 1.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.12 Billion | +0.42% |
| 2025 | $2.12 Billion | +105.04% |
| 2024 | $1.03 Billion | -25.57% |
| 2023 | $1.39 Billion | +97.21% |
| 2022 | $702.76 Million | -11.39% |
| 2021 | $793.06 Million | +20.96% |
| 2020 | $655.65 Million | -11.52% |
| 2019 | $741.04 Million | +192.64% |
| 2018 | $253.23 Million | -68.54% |
| 2017 | $804.84 Million | -21.08% |
| 2016 | $1.02 Billion | -14.91% |
| 2015 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Avadel Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.12 Billion USD |
| MoneyControl | $2.12 Billion USD |
| MarketWatch | $2.12 Billion USD |
| marketcap.company | $2.12 Billion USD |
| Reuters | $2.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more